GLP-1s & Weight Loss
Tirzepatide
← Back to Library
Label-verified Metabolic Incretin
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or human-trial protocol above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 5, 10, 15, 20, 30, 40, 50, 60 mg
Dosing window: Anytime
Receptor / target: GLP-1; GIP
Properties: Incretin
Pre-mixed: No
Protocol examples
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 2.5mg once weekly | Initiation phase. Do not skip to avoid severe GI distress. |
| Weeks 5-8 | 5.0mg once weekly | Standard therapeutic dose for steady fat loss. |
| Weeks 9-12 | 7.5mg once weekly | Escalate only if weight loss stalls. |
| Weeks 13-16 | 10.0mg once weekly | Advanced phase. |
| Weeks 17-20 | 12.5mg once weekly | Pre-maximum phase. |
| Weeks 21+ | 15.0mg once weekly | Maximum limit. Do not exceed. |
Protocol example from the source dataset; verify against the evidence status and listed sources.
Alternative: Biohacker Start
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 1.0mg to 1.5mg once weekly | Lower starting point for highly sensitive subjects. |
| Weeks 5-8 | 2.5mg once weekly | Standard initiation. |
| Weeks 9+ | Titrate up by 1.0mg to 2.5mg as needed. | Follows standard protocol from here. |
Alternative example from the source dataset; not an approved-label regimen unless marked above.
Alternative: Split Dosing
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 1.25mg every 3.5 days | E.g., Monday and Thursday. Mitigates day-2 lethargy and day-6 appetite return. |
| Weeks 5-8 | 2.5mg every 3.5 days | Equals 5.0mg weekly. |
| Weeks 9-12 | 3.75mg every 3.5 days | Equals 7.5mg weekly. |
Alternative example from the source dataset; not an approved-label regimen unless marked above.
Protocol logic check
Protocol context: Weight-loss protocols should not pretend fat loss is only willpower. The logic is appetite signaling, GI tolerance, adherence, protein, resistance training, hydration, and preserving lean mass while the dose changes. Entry context: target (GLP-1; GIP); route Subcutaneous; timing Anytime. Label/trial anchors carry more weight than forum-style escalation. FDA/safety flags lower confidence and raise the evidence bar for any claimed benefit. Compatibility is conditional: a reasonable solo compound can become inappropriate once a contraindicated partner is added. Common diet-myth context matters: rapid vs slow loss is individual, fasting only helps when adherence improves, and protein/training protect lean mass during aggressive deficits.
Independent evidence
Approved label dosing: Zepbound starts at 2.5 mg SC once weekly for 4 weeks, then 5 mg once weekly; increases are in 2.5 mg increments after at least 4 weeks on the current dose. Weight reduction maintenance doses are 5, 10, or 15 mg weekly; maximum is 15 mg weekly.
Clinical trial regimen(s): SURMOUNT-1 studied once-weekly tirzepatide 5, 10, and 15 mg for 72 weeks.
Independent safety notes: FDA warns about adverse events from compounded semaglutide or tirzepatide doses beyond label dosing, faster titration, or more frequent dosing.
Regulatory status: approved drug label available
Storage
Refrigerate 2-8 C; do not freeze; keep in original carton away from light. Zepbound vial labeling allows room-temperature storage up to 30 C with 30-day discard rules.
Contraindications & cautions
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.
- Personal or family history of Medullary Thyroid Carcinoma (MTC).
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Personal or family history of thyroid C-cell tumors.
- Active or history of acute pancreatitis.
- Severe gastroparesis or clinically significant delayed gastric emptying.
- Type 1 diabetes mellitus.
- Diabetic ketoacidosis.
- Pregnancy: discontinue at least 2 months prior to planned conception; fetal risk not established.
- Breastfeeding: insufficient safety data.
- Known hypersensitivity or anaphylaxis to tirzepatide or any formulation excipient.
- Concurrent use with any other GLP-1 receptor agonist (e.g., semaglutide, liraglutide, dulaglutide): direct pharmacological overlap.
- Concurrent use with retatrutide, mazdutide, survodutide, or any other incretin agonist: additive receptor conflict.
- History of suicidal ideation or prior suicide attempts: monitor closely.
- Planned general anesthesia or elective surgery: delayed gastric emptying significantly raises pulmonary aspiration risk; follow pre-operative fasting and discontinuation protocols.
- Severe inflammatory bowel disease or active Crohn's disease: GI motility impairment may worsen symptoms.
- End-stage renal disease on dialysis: limited clinical evidence; use with extreme caution.
- Pediatric use under age 18: safety and efficacy not established.
Possible side effects
Evidence varies by item. Some points come from labels, published literature, or regulatory context; others are mechanism-based cautions from the source dataset. Use the sources below to verify details.
- Nausea: most common adverse effect; typically peaks in the first 4 weeks of each dose escalation.
- Diarrhea.
- Vomiting.
- Constipation.
- Abdominal pain and cramping.
- Dyspepsia (indigestion).
- Abdominal distension and bloating.
- Decreased appetite and dysgeusia (altered taste).
- Belching and flatulence.
- Gastroparesis: delayed gastric emptying; may persist even with pre-operative fasting.
- Gastroesophageal reflux disease (GERD) exacerbation.
- Fatigue and lethargy: frequently secondary to acute caloric deficit.
- Day-2 post-injection lethargy: commonly reported phenomenon, particularly in the 12-36 hour window following injection.
- Headache.
- Dizziness.
- Hypoglycemia: risk elevated when combined with insulin or sulfonylureas; rare when used as monotherapy.
- Acute pancreatitis: documented in case reports; causal relationship under ongoing investigation.
- Acute kidney injury: primarily mediated by dehydration from GI side effects.
- Cholelithiasis (gallstones) and acute cholecystitis: risk increases with dose and rate of weight loss.
- Diabetic retinopathy complications: risk elevated in subjects with pre-existing retinopathy during rapid glycemic correction.
- Thyroid C-cell tumor risk: confirmed in rodent models; human risk remains under evaluation; monitor for neck mass, hoarseness, or dysphagia.
- Alopecia (hair loss): reported in post-marketing surveillance.
- Injection site reactions: redness, itching, bruising at administration site.
- Anaphylaxis and angioedema: rare but documented.
- Pulmonary aspiration risk under general anesthesia: secondary to delayed gastric emptying.
- Rapid weight regain upon discontinuation: without lifestyle intervention, significant weight rebound is expected within months of cessation.
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
Sources
- https://the source dataset.com/peptide-codex.php
- https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
- https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
- https://pubmed.ncbi.nlm.nih.gov/35658024/
- https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro
- https://health-products.canada.ca/dpd-bdpp/info?code=106085&lang=eng
- PubMed search: Tirzepatide
- DailyMed label search: tirzepatide